67% in Ovarian. 50% in Prostate. Without the Bone Marrow Beating.
Acerand Therapeutics drops Phase I/II data for ACE-106, a PARP1-selective inhibitor with response rates that put it in best-in-class territory.
Jeff Martin
Mesoblast Puts a CAR on a Stem Cell
Mesoblast licenses Mayo Clinic CAR technology to build CAR-MSC therapies for autoimmune disease.
An EP300/CBP Inhibitor Designed to Clear Before It Hurts
Opna Bio's OPN-6602, an oral EP300/CBP dual inhibitor, receives FDA Fast Track for relapsed myeloma.
RNA-Targeting Small Molecules Pass Their First Pharma Test
Wayfinder Biosciences advances Daiichi Sankyo collaboration on RNA-targeting small molecules to lead optimization.
A Dual-Pathway Peptide for the Pain Chemo Leaves Behind
Dogwood Therapeutics gets FDA IND acceptance for SP16 in chemotherapy-induced pain, funded by NCI.
An Implantable Muscle Interface for Amputees Enters First-in-Human
Phantom Neuro gets approval for first-in-human CYBORG trial of muscle-machine interface in amputees.
20 Minutes to Burn a Pancreatic Tumor
Sonire Therapeutics closes $18M Series A for focused ultrasound ablation in pancreatic cancer.
A CAR-T Built on Natural Killer Cell Wiring
Verismo Therapeutics raises $28M to advance KIR-CAR T cell platform ahead of AACR data.
A Tumor-Targeted IL-12 Doubles the Response Rate in MSS Colorectal Cancer
PDS Biotech posts 78% ORR with tumor-targeted IL-12 in MSS colorectal cancer.
Lilly Bought a Dual-Payload ADC Before It Hit the Clinic. Here’s Why.
Eli Lilly acquires CrossBridge Bio and its dual-payload ADC platform before any clinical data.